Elixinol Sustains Margin Gains and Cash Flow Momentum in Q1 FY26

• Q1 FY26 revenue stable at $3.5 million
• Gross margin improved by 8 percentage points to 45%
• Healthy Chef e-commerce sales up 25% year-on-year
• Operating expenses cut by 29% year-on-year
• Second consecutive quarter of positive underlying operating cash flow

Margin Expansion Drives Profitability Pathway

Elixinol Wellness (ASX:EXL) has delivered a solid start to FY26 with Q1 revenue holding steady at $3.5 million, but it’s the margin story that stands out. The company boosted its gross margin to 45%, an 8 percentage point lift from the prior year, reflecting a strategic pivot towards higher-margin product lines and channels. This margin expansion underpins a 36% increase in gross profit for its Australian operations, signalling improved revenue quality amid a stable top line.

Strong e-commerce sales of The Healthy Chef brand, up 25% year-on-year, contributed significantly to this margin improvement. The Healthy Chef now accounts for 26% of total revenue, up from 21% a year earlier, highlighting the growing importance of owned channels and premium brands to Elixinol’s portfolio. The launch of Metabolic Burn and the traction gained by Protein Water further illustrate consumer appetite for convenient, lower-calorie functional nutrition products.

Cost Discipline and Cash Flow Turnaround

Elixinol’s cost management efforts have yielded tangible results with operating expenses down 29% year-on-year. Staff costs fell by 28%, marketing expenses by 37%, and distribution costs by 24%, reflecting a leaner cost base aligned with the company’s refocused strategy. This disciplined approach has driven the second consecutive quarter of positive underlying operating cash flow, a notable turnaround after consistent outflows last year, including a peak operating cash outflow of $1.27 million in Q3 FY25.

Despite a modest operating cash outflow of $0.14 million in the quarter, the underlying cash flow measure excludes finance costs and non-recurring items, painting a more favourable picture of operational efficiency. With a cash balance of $1.2 million and access to various financing facilities, including trade debtor finance and e-commerce revenue advances, Elixinol appears well-positioned to sustain its operational momentum.

Strategic Outlook and Growth Opportunities

CEO Natalie Butler emphasised the resilience of demand amid ongoing geopolitical uncertainty, with a predominantly Australian supply chain providing stability against moderate freight cost pressures. The company anticipates building on Q1 momentum in Q2, supported by a robust pipeline of B2B and retail channel opportunities, innovative product launches rolling out into Coles, and a substantial hemp harvest underpinning order flow.

Chair Gavin Evans highlighted the company’s repositioning over the past six months, noting the clear evidence of strategy execution through margin gains and improved cash management. Elixinol’s focus on premium-branded health food assets and ongoing exploration of M&A opportunities could accelerate growth, complementing organic expansion efforts.

This update follows Elixinol’s recent progress in cost reductions and leadership changes that set the stage for profitability, as detailed in its cost cuts and new leadership in FY25. The company’s ability to sustain margin improvements and positive cash flow while navigating a complex market environment will be critical to watch in the coming quarters.

Bottom Line?

Elixinol’s margin gains and disciplined cost base are translating into improved cash flow, but sustaining growth amid supply chain and market uncertainties remains the key challenge.

Questions in the middle?

• Will Elixinol’s new product launches and channel expansions translate into sustained revenue growth in Q2 and beyond?
• How will the company navigate potential cost pressures from freight and raw materials in its predominantly Australian supply chain?
• What role will M&A play in accelerating Elixinol’s growth trajectory and portfolio diversification?